Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of Sulfopin and Abemaciclib treatment on gene expression in mouse TNBC

ABSTRACT: Effect of Sulfopin and Abemaciclib treatment on gene expression in mouse TNBC

PROVIDER: PRJNA971963 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24526117_1.fastq.gz	Fastqsanger.gz
	SRR24526117_2.fastq.gz	Fastqsanger.gz
	SRR24526118_1.fastq.gz	Fastqsanger.gz
	SRR24526118_2.fastq.gz	Fastqsanger.gz
	SRR24526119_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Effect of Sulfopin and Abemaciclib treatment on gene expression in mouse TNBC

Project description:To investigate the role of combined PIN1 and CDK4 inhibition in the regulation of immune response, we performed RNA sequencing of TNBC tumors after treatment with Sulfopin, Abemaciclib or their combination

2024-03-08 | GSE232422 | GEO

Cut&Run SU-DIPG13 cells treated Sulfopin/Vorinostat/Sulfopin+Vorinostat or DMSO

Project description:Diffuse midline gliomas (DMG) are aggressive pediatric tumors of the central nervous system that are highly resistant to treatments and are inevitably fatal. Lysine to methionine substitution of residue 27 on histone H3 (H3-K27M) is a driver mutation in DMGs, reshaping the epigenetic landscape of these cells to promote tumorigenesis. H3-K27M gliomas are characterized by deregulation of histone acetylation and methylation pathways, as well as the oncogenic MYC pathway. In search of effective treatment, we examined the therapeutic potential of dual targeting of histone deacetylases (HDACs) and MYC in these tumors. Treatment of H3-K27M patient-derived cells with Sulfopin, an inhibitor shown to block MYC-driven tumors in vivo, in combination with the HDAC inhibitor Vorinostat, resulted in substantial decrease in cell viability. Moreover, transcriptome and epigenome profiling revealed synergistic effect of this drug combination in downregulation of prominent oncogenic pathways such as mTOR. Finally, in vivo studies of patient-derived orthotopic xenograft models showed significant tumor size reduction in mice treated with the drug combination. These results highlight the combined treatment of Sulfopin and Vorinostat as a promising therapeutic approach for these aggressive tumors.

2024-06-24 | GSE221611 | GEO

Effect of Omomyc treatment on human TNBC MDAMB231 cell line

Project description:Effect of Omomyc treatment on human TNBC MDAMB231 cell line

| PRJNA729983 | ENA

MARS-seq on SU-DIPG13 cells treated Sulfopin/Vorinostat/Sulfopin+Vorinostat or DMSO

2024-06-24 | GSE221612 | GEO

Sulfopin, a covalent inhibitor of Pin1, blocks Myc-driven tumors in vivo

Project description:The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and inactivate tumor suppressors. However, despite considerable efforts, Pin1 has remained an elusive drug target. Here, we screened an electrophilic fragment library to identify covalent inhibitors targeting Pin1’s active site Cys113, leading to the development of Sulfopin, a nanomolar Pin1 inhibitor. Sulfopin is highly selective, as validated by two independent chemoproteomics methods, achieves potent cellular and in vivo target engagement, and phenocopies Pin1 genetic knockout. Pin1 inhibition had only a modest effect on cancer cell line viability. Still, Sulfopin induced downregulation of c-Myc target genes, reduced tumor progression and conferred survival benefit in murine and zebrafish models of MYCN-driven neuroblastoma, and in a murine model of pancreatic cancer. Our results demonstrate that Sulfopin is a suitable chemical probe for assessing Pin1-dependent pharmacology in cells and in vivo, and that Pin1 warrants further investigation as a potential cancer drug target.

2021-04-01 | GSE166786 | GEO

FEC + OV treatment of TNBC tumors

Project description:FEC + OV treatment of TNBC tumors

| PRJNA640141 | ENA

RNA-seq of BJ human fibroblasts treated with doxorubicin or abemaciclib compared to vehicle-treated counterpart

Project description:This experiment follows the transcriptional response of human fibroblasts (BJ) to two different drug treatments (doxorubicin and abemaciclib) in comparison to treatment with vehicle (water). The two drugs are used in cancer care and their mechanism of action entails proliferative arrest. Doxorubicin is a member of the anthracycline family and acts as a topoisomerase II inhibitor. Abemaciclib is an inhibitor of the Cyclin Dependent Kinases (CDK) 4/6 which arrest cell cycle at the G1/S phase.

2021-11-29 | E-MTAB-7642 | biostudies-arrayexpress

RNA-seq of detecting the effect of CDK4&6 inhibitor Abemaciclib and VSV-M51 in glioma

Project description:The RNA-seq data provided evidence that CDK4&6 inhibitor Abemaciclib and VSV-M51 increase the oncolytic effect in glioma

2022-06-01 | GSE166914 | GEO

Transcriptomic analysis in murine mammary carcinoma tissue after treatment with control vehicle or abemaciclib

Project description:We measured changes in expression of 3,826 genes in MMTV-rtTA/tetO-HER2 mammary carcinoma tissue after treatment with control vehicle or abemaciclib

2017-08-17 | GSE99061 | GEO

Cut&Run SU-DIPG13 cells treated Sulfopin/Vorinostat/Sulfopin+Vorinostat or DMSO

Project description:Cut&Run SU-DIPG13 cells treated Sulfopin/Vorinostat/Sulfopin+Vorinostat or DMSO

| PRJNA915081 | ENA